Trial · NCT04995029
Participant flow36
How many started, completed or left each group, period by period.
1 to 20 of 36
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Induction Phase | STARTED | Induction Phase: Rapid Induction | 518 | |
| Induction Phase | STARTED | Induction Phase: Standard of Care Induction | 267 | |
| Induction Phase | STARTED | Maintenance Phase: Extended-release Buprenorphine 100 mg | 0 | |
| Induction Phase | STARTED | Maintenance Phase: Extended-release Buprenorphine 300 mg | 0 | |
| Induction Phase | Received TM BUP | Induction Phase: Rapid Induction | 513 | |
| Induction Phase | Received TM BUP | Induction Phase: Standard of Care Induction | 264 | |
| Induction Phase | Received TM BUP | Maintenance Phase: Extended-release Buprenorphine 100 mg | 0 | |
| Induction Phase | Received TM BUP | Maintenance Phase: Extended-release Buprenorphine 300 mg | 0 | |
| Induction Phase | Received RBP-6000 Injection 1 | Induction Phase: Rapid Induction | 444 | |
| Induction Phase | Received RBP-6000 Injection 1 | Induction Phase: Standard of Care Induction | 159 | |
| Induction Phase | Received RBP-6000 Injection 1 | Maintenance Phase: Extended-release Buprenorphine 100 mg | 0 | |
| Induction Phase | Received RBP-6000 Injection 1 | Maintenance Phase: Extended-release Buprenorphine 300 mg | 0 | |
| Induction Phase | Received RBP-6000 Injection 2 | Induction Phase: Rapid Induction | 339 | |
| Induction Phase | Received RBP-6000 Injection 2 | Induction Phase: Standard of Care Induction | 145 | |
| Induction Phase | Received RBP-6000 Injection 2 | Maintenance Phase: Extended-release Buprenorphine 100 mg | 0 | |
| Induction Phase | Received RBP-6000 Injection 2 | Maintenance Phase: Extended-release Buprenorphine 300 mg | 0 | |
| Induction Phase | COMPLETED | Induction Phase: Rapid Induction | 298 | |
| Induction Phase | COMPLETED | Induction Phase: Standard of Care Induction | 137 | |
| Induction Phase | COMPLETED | Maintenance Phase: Extended-release Buprenorphine 100 mg | 0 | |
| Induction Phase | COMPLETED | Maintenance Phase: Extended-release Buprenorphine 300 mg | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04995029/flow